Advertisement
GSK vs JNJ
Which Stock Would AI Choose? GlaxoSmithKline (GSK) vs. Johnson & Johnson (JNJ) Stock Comparison
Key Takeaways
- GlaxoSmithKline (GSK) has seen recent momentum from FDA approval of its first lung cancer drug, Jideytro, alongside ongoing pipeline advancements in oncology and vaccines.
- Johnson & Johnson (JNJ) delivered strong quarterly results with raised full-year guidance, driven by diversified growth across innovative medicines and MedTech segments.
- Both companies operate in the healthcare sector but differ in scale, with JNJ maintaining a larger market capitalization and broader product portfolio.
- Recent market activity shows JNJ benefiting from consistent earnings beats and positive sentiment, while GSK focuses on regulatory wins to support long-term positioning.
- Relative performance highlights trade-offs between GSK's targeted pipeline catalysts and JNJ's demonstrated operational stability and growth acceleration.
- Market sentiment remains constructive for both amid sector dynamics, though each faces distinct risk factors tied to product cycles and regulatory environments.
Introduction
This comparison examines GlaxoSmithKline (GSK) and Johnson & Johnson (JNJ), two established healthcare companies with significant presence in pharmaceuticals and related areas. The analysis focuses on observable factors such as recent performance trends, business fundamentals, and market positioning to assist investors and traders evaluating relative opportunities. Professionals monitoring sector rotation, dividend-oriented strategies, or AI-driven signals may find the side-by-side review useful for assessing diversification within healthcare equities.
GlaxoSmithKline (GSK) Overview and Recent Performance
GlaxoSmithKline (GSK) is a global biopharmaceutical company focused on specialty medicines, vaccines, and general medicines. In recent weeks, the stock has responded positively to regulatory developments, including U.S. Food and Drug Administration approval of Jideytro for ROS1-positive non-small cell lung cancer, marking an entry into precision oncology. Additional updates on Shingrix and pipeline progress in areas such as oncology and respiratory conditions have contributed to sentiment. Broader market activity reflects a balance between these catalysts and the company's positioning ahead of its second-quarter results, scheduled for late July 2026. Performance has shown resilience over the past year, with the American Depositary Shares trading near recent levels around $51 amid ongoing emphasis on innovation.
Johnson & Johnson (JNJ) Overview and Recent Performance
Johnson & Johnson (JNJ) is a diversified healthcare company with operations spanning innovative medicines, MedTech, and consumer health. Recent market activity has been supported by solid quarterly results, including first-quarter sales growth of 9.9% to $24.1 billion and subsequent second-quarter figures that exceeded estimates, prompting further upward revisions to full-year guidance. Key drivers include momentum in products such as Tremfya and Darzalex, helping offset legacy impacts, alongside MedTech contributions. The stock has maintained an upward trajectory in recent weeks, trading in ranges above $230 with year-to-date gains reflecting investor confidence in operational execution. Sentiment has benefited from consistent delivery on raised outlooks and broad-based portfolio strength.
Trending AI Robots
Tickeron operates a platform featuring hundreds of AI trading bots that analyze and trade thousands of different tickers across various asset classes. Only the strongest performers suited to prevailing conditions are featured in the curated Trending AI Robots section. The page currently highlights 25 best AI trending bots selected from a total of 351 available options. These bots encompass a range of trading styles, strategies, timeframes, performance metrics, and ticker sets, allowing users to explore options aligned with technical or fundamental approaches and different volatility environments. All AI trading bots have different trading styles, strategies, timeframes, performances, statistics, and sets of tickers they trade. For more details, visit Trending AI Robots.
Head-to-Head Comparison
GlaxoSmithKline (GSK) and Johnson & Johnson (JNJ) both participate in the healthcare sector but diverge in business model and scale. JNJ operates with greater diversification across pharmaceuticals and medical devices, providing broader exposure compared to GSK's emphasis on specialty medicines and vaccines. Growth drivers for GSK center on pipeline approvals and new indications, while JNJ benefits from established product momentum and acquisitions supporting sustained revenue expansion. Recent momentum has favored JNJ through multiple guidance increases and earnings consistency, contrasting with GSK's more event-driven responses to regulatory news. Risk factors include GSK's reliance on successful commercialization of newer assets and JNJ's exposure to competitive pressures in key therapeutic areas. Sector exposure remains similar, yet market sentiment reflects differing paces of verifiable progress, with JNJ demonstrating steadier positioning in the current environment.
Tickeron AI Verdict
Based on observable factors including trend consistency, earnings delivery, and relative catalysts, Tickeron’s AI would currently assign a higher probabilistic weighting to Johnson & Johnson (JNJ) over GlaxoSmithKline (GSK). JNJ exhibits more consistent recent performance metrics and guidance revisions that align with stable positioning, whereas GSK shows promise through targeted approvals but with greater variability tied to pipeline milestones. This assessment draws from verifiable market data rather than forecasts.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is GSK is a Buy and JNJ is a StrongBuy.
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
GSK’s FA Score shows that 0 FA rating(s) are green whileJNJ’s FA Score has 4 green FA rating(s).
- GSK’s FA Score: 0 green, 5 red.
- JNJ’s FA Score: 4 green, 1 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
GSK’s TA Score shows that 3 TA indicator(s) are bullish while JNJ’s TA Score has 3 bullish TA indicator(s).
- GSK’s TA Score: 3 bullish, 6 bearish.
- JNJ’s TA Score: 3 bullish, 4 bearish.
Price Growth
GSK (@Pharmaceuticals: Major) experienced а -3.30% price change this week, while JNJ (@Pharmaceuticals: Major) price change was +1.98% for the same time period.
The average weekly price growth across all stocks in the @Pharmaceuticals: Major industry was +1.96%. For the same industry, the average monthly price growth was +2.35%, and the average quarterly price growth was +2.74%.
Reported Earning Dates
GSK is expected to report earnings on Oct 28, 2026.
JNJ is expected to report earnings on Oct 20, 2026.
Industries' Descriptions
@Pharmaceuticals: Major (+1.96% weekly)The Major Pharmaceuticals industry includes companies that are involved in various processes of creating drugs to treat/prevent diseases. These companies engage in research, testing and manufacturing, as well as the distribution of pharmaceuticals into markets. Johnson & Johnson, Merck & Co., Inc., Pfizer Inc. and Novartis are among the largest companies in this category.
| GSK | JNJ | GSK / JNJ | |
| Capitalization | 101B | 632B | 16% |
| EBITDA | 9.68B | 34B | 28% |
| Gain YTD | 4.338 | 27.449 | 16% |
| P/E Ratio | 15.85 | 30.40 | 52% |
| Revenue | 33.2B | 97.9B | 34% |
| Total Cash | 3.11B | 20.8B | 15% |
| Total Debt | 18.2B | 49B | 37% |
GSK | JNJ | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 60 | 35 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 60 Fair valued | 12 Undervalued | |
PROFIT vs RISK RATING 1..100 | 44 | 5 | |
SMR RATING 1..100 | 35 | 38 | |
PRICE GROWTH RATING 1..100 | 54 | 28 | |
P/E GROWTH RATING 1..100 | 59 | 13 | |
SEASONALITY SCORE 1..100 | 55 | 65 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
JNJ's Valuation (12) in the Pharmaceuticals Major industry is somewhat better than the same rating for GSK (60). This means that JNJ’s stock grew somewhat faster than GSK’s over the last 12 months.
JNJ's Profit vs Risk Rating (5) in the Pharmaceuticals Major industry is somewhat better than the same rating for GSK (44). This means that JNJ’s stock grew somewhat faster than GSK’s over the last 12 months.
GSK's SMR Rating (35) in the Pharmaceuticals Major industry is in the same range as JNJ (38). This means that GSK’s stock grew similarly to JNJ’s over the last 12 months.
JNJ's Price Growth Rating (28) in the Pharmaceuticals Major industry is in the same range as GSK (54). This means that JNJ’s stock grew similarly to GSK’s over the last 12 months.
JNJ's P/E Growth Rating (13) in the Pharmaceuticals Major industry is somewhat better than the same rating for GSK (59). This means that JNJ’s stock grew somewhat faster than GSK’s over the last 12 months.
| GSK | JNJ | |
|---|---|---|
| RSI ODDS (%) | N/A | 7 days ago 34% |
| Stochastic ODDS (%) | 2 days ago 57% | 2 days ago 53% |
| Momentum ODDS (%) | 2 days ago 44% | 2 days ago 51% |
| MACD ODDS (%) | 2 days ago 42% | 2 days ago 35% |
| TrendWeek ODDS (%) | 2 days ago 53% | 2 days ago 46% |
| TrendMonth ODDS (%) | 2 days ago 49% | 2 days ago 49% |
| Advances ODDS (%) | 7 days ago 62% | 9 days ago 45% |
| Declines ODDS (%) | 2 days ago 54% | 15 days ago 42% |
| BollingerBands ODDS (%) | 2 days ago 45% | N/A |
| Aroon ODDS (%) | 2 days ago 64% | 2 days ago 44% |
Advertisement
GSK and
Correlation & Price change
A.I.dvisor indicates that over the last year, GSK has been loosely correlated with NVS. These tickers have moved in lockstep 64% of the time. This A.I.-generated data suggests there is some statistical probability that if GSK jumps, then NVS could also see price increases.
JNJ and
Correlation & Price change
A.I.dvisor indicates that over the last year, JNJ has been loosely correlated with PFE. These tickers have moved in lockstep 59% of the time. This A.I.-generated data suggests there is some statistical probability that if JNJ jumps, then PFE could also see price increases.